公开(公告)号：US20180179282A1

公开(公告)日：2018-06-28

申请号：US15735055

申请日：2016-06-13

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Josephine M. Cardarelli ,  Wendy L. Clemens ,  Glenn S. Kroog ,  Daniel E. Lopes de Menezes ,  Chin Pan ,  Paul D. Ponath ,  Jean Viallet

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/24

CPC classification number: C07K16/2818 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  A61P35/00 ,  C07K16/24 ,  C07K16/2827 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76

Abstract: This disclosure provides a method for treating a subject afflicted with a cancer comprising administering to the subject a combination of therapeutically effective amounts of an antibody or an antigen-binding portion thereof that binds specifically to Programmed Death-1 (PD-1) or to Programmed Death Ligand-1 (PD-L1), and an antibody or an antigen-binding portion thereof that binds specifically to C-X-C Chemokine Receptor 4 (CXCR4) or to C-X-C motif chemokine 12 (CXCL12). The disclosure also provides a kit for treating a subject afflicted with a cancer, the kit comprising one or more dosages of an antibody or an antigen-binding portion thereof that binds specifically to PD-1 or to PD-L1, one or more dosages of an antibody or an antigen-binding portion thereof that binds specifically to CXCR4 or to CXCL12, and instructions for using the antibodies or portions thereof for treating the subject.